How I treat double-hit lymphoma
JW Friedberg - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
The 2016 revision of the World Health Organization (WHO) classification for lymphoma has
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …
From genetics to the clinic: a translational perspective on follicular lymphoma
S Huet, P Sujobert, G Salles - Nature Reviews Cancer, 2018 - nature.com
Follicular lymphoma (FL) is the most frequent indolent B cell lymphoma and is still
considered to be incurable. In recent years, whole-exome sequencing studies of large …
considered to be incurable. In recent years, whole-exome sequencing studies of large …
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study
PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …
years of rituximab maintenance after first-line immunochemotherapy significantly improved …
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …
disease course; however, survival based on lines of treatment remains poorly described in …
NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …
common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of …
Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant …
C Casulo, JW Friedberg, KW Ahn, C Flowers… - Biology of blood and …, 2018 - Elsevier
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years
of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from …
of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from …
Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular …
S Luminari, A Ferrari, M Manni, A Dondi… - Journal of Clinical …, 2018 - ascopubs.org
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
M Federico, MDC Barrigón, L Marcheselli… - The Lancet …, 2018 - thelancet.com
Background Histological transformation of follicular lymphoma to aggressive lymphoma is a
serious event with a substantial effect on patient outcome. The aim of the Aristotle study was …
serious event with a substantial effect on patient outcome. The aim of the Aristotle study was …
Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk
Follicular lymphoma (FL) is an indolent cancer of mature B-cells but with ongoing risk of
transformation to more aggressive histology over time. Recurrent mutations associated with …
transformation to more aggressive histology over time. Recurrent mutations associated with …
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I …
M Shadman, H Li, L Rimsza, JP Leonard… - Journal of Clinical …, 2018 - ascopubs.org
Purpose SWOG S0016 was a phase III randomized study that compared the safety and
efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and …
efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and …